MigVax to Start Human Trials for COVID-19 Vaccine This Summer
Israeli biotech firm MigVax is set to commence human trials for a COVID-19 vaccine this summer. The company has secured a $12 million investment to speed up development, aiming to manufacture doses quickly and affordably.
MigVax will initiate Phase 1 clinical trials in humans during the summer, with a duration of six to nine months. This follows successful safety and efficacy assessments in rodents, scheduled to begin next month. The company's unique approach uses bacterial fermentation, ensuring the vaccine is safe for those with compromised immune systems.
The vaccine is being adapted from an existing one used against infectious bronchitis virus (IBV) in poultry. MigVax believes this technology can be effectively applied to combat COVID-19. The company aims to produce millions of doses swiftly and at a low cost, contributing significantly to global vaccination efforts.
With the $12 million investment led by Perceptive Advisors, MigVax is poised to accelerate its COVID-19 vaccine development. Human trials starting this summer mark a significant step forward, bringing a potentially safe, effective, and affordable COVID-19 vaccine closer to reality.
